MAP2K7 and myeloproliferative disorder: In MPN, combining JAK and MEK inhibition has shown a suppression of MEK/ERK activation in JAK2V617F and MPLW515L mice with increased efficacy and reversal of fibrosis to an extent not seen with JAK inhibitors alone (63).